Synapse - Works

Results (5377)

Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma

Meeting Abstract

Costa, B. A.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
Blood (2024)

Fulltext@MSK | Save

Defining the rates of cytokine release syndrome associated with talquetamab step-up doses

Meeting Abstract

Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R. S.; Wang, A. X.; Korde, N.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; more...
Blood (2024)

Fulltext@MSK | Save

Efficacy of daratumumab, pomalidomide and dexamethasone compared to daratumumab, carfilzomib and dexamethasone in high risk relapsed multiple myeloma: multicenter real-world experience

Meeting Abstract

Magee, G.; Mansour, R.; Chang, M. R.; Atrash, S.; Ahmed, N.; Mushtaq, M. U.; Ouchveridze, E.; Abdallah, A.; Paul, B.; Green, K. M.; more...
Blood (2024)

Fulltext@MSK | Save

Functional geriatric assessment tests predict toxicity rates in functional high risk myeloma patients treated with daratumumab, carfilzomib, lenalidomide and dexamethasone in a prospective clinical trial

Meeting Abstract

Shmuel, R.; Tellem, R.; Gatt, M. E.; Lavi, N.; Ganzel, C.; Luttwak, E.; Chubar, E.; Rouvio, O.; Vaxman, I.; Pasvolsky, O.; more...
Blood (2024)

Fulltext@MSK | Save

Comparison of acute kidney injury in patients with relapsed or refractory multiple myeloma following CAR T-cell and bispecific antibody therapies

Meeting Abstract

Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B. A.; Farzana, T.; Shaikh, A.; Latcha, S.; Gutgarts, V.; Jurgens, E. M.; more...
Blood (2024)

Fulltext@MSK | Save

Body mass index trajectory during triplet induction therapy: Clinical implications in newly diagnosed multiple myeloma

Meeting Abstract

Thirugnanasambandam, R. P.; Firestone, R. S.; Derkach, A.; Furberg, H.; Shekarkhand, T.; Rueda, C.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; Patel, D.; more...
Blood (2024)

Fulltext@MSK | Save

Trial in progress: An open-label clinical trial of RVU120 as monotherapy and in combination with ruxolitinib in patients with intermediate or high-risk, primary or secondary myelofibrosis (POTAMI-61)

Meeting Abstract

Kuklik, R.; Falkowski, A.; Zaroogian, Z.; Mazan, M.; Szymula, A.; Wilkinson, G.; Adamczyk, E.; Woznicki, J.; Micek, M.; Coelho, D.; more...
Blood (2024)

Fulltext@MSK | Save

Early anemia response in patients with myelofibrosis treated with pacritinib in real-word clinical settings

Meeting Abstract

Mascarenhas, J. O.; Marrone, M.; Morere, L.; Oladapo, A.; Suthar, P.; Sura, T.; Vasudevan, A.; Vredenburg, M.; Zeng, J.; Rampal, R.
Blood (2024)

Fulltext@MSK | Save

Real-word effectiveness of pacritinib in patients with myelofibrosis who have thrombocytopenia and anemia

Meeting Abstract

Rampal, R.; Marrone, M.; Morere, L.; Oladapo, A.; Suthar, P.; Sura, T.; Vasudevan, A.; Vredenburg, M.; Zeng, J.; Mascarenhas, J. O.
Blood (2024)

Fulltext@MSK | Save

Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma

Meeting Abstract

Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
Blood (2024)

Fulltext@MSK | Save